Related by context. All words. (Click for frequent words.) 78 Phase 2b Clinical Trial 77 Meets Primary Endpoint 77 Hsp# Inhibitor 76 CYT# potent vascular disrupting 76 Phase 2a Trial 76 Phase 2a Clinical Trial 75 Pivotal Phase III 75 Preclinical Data 75 receptor tyrosine kinase inhibitor 75 Talabostat 75 Romidepsin 75 Phase IIb Clinical Trial 75 Aflibercept 75 Blinatumomab 75 Kinase Inhibitor 75 Oral Fingolimod 74 Clinical Trial Results 74 FOLOTYN ® 74 Combination REOLYSIN R 74 Initiate Phase 74 Completes Patient Enrollment 74 HDAC Inhibitor 74 Hormone Refractory Prostate Cancer 74 Initiates Enrollment 74 Aurora Kinase 74 Phase III Clinical Trial 74 Enzastaurin 74 Deforolimus 74 Phase 2b Trial 74 Anti Tumor 74 Methylnaltrexone 74 Anti Tumor Activity 74 Antitumor Activity 74 Maribavir 74 Novel Antibiotic 74 PKC# 74 Omacetaxine 74 Successfully Completes Phase 74 erlotinib Tarceva ® 73 Phase IIb Trial 73 Investigational Compound 73 pralatrexate injection folate analogue 73 Investigational Treatment 73 Seliciclib 73 Voreloxin 73 Initiates Clinical 73 Phase 2b Study 73 Single Dose 73 Initiates Phase II 73 Metastatic Melanoma 73 Randomized Phase 73 Pralatrexate 73 Mg Usa 73 non nucleoside inhibitor 73 mertansine 73 MEK Inhibitor 73 nucleoside analog 73 Bucindolol 73 Study Evaluating 73 Golimumab 73 Cutaneous T 73 Belimumab 73 Novel Oral 73 Pafuramidine 73 Treatment Naïve 73 Preclinical Models 73 Pivotal Phase 73 Ridaforolimus 73 intravesical infusion therapy 73 Drug Candidate 73 Vicriviroc 73 Randomized Double blind 72 Elotuzumab 72 Dasatinib 72 Tezampanel 72 Anticancer Compound 72 ADP receptor antagonist 72 Presents Positive 72 oral prodrug 72 Complicated Skin 72 Phase III Clinical Trials 72 CYP#A# CYP#D# 72 Tyrosine Kinase Inhibitor 72 Humanized Anti 72 Epidermal Growth Factor Receptor 72 INSPIRE Trial Phase III 72 Carfilzomib 72 Muraglitazar 72 First Patient Dosed 72 Dose Escalation 72 CCR9 antagonist 72 Initiates Clinical Trial 72 Myelodysplastic Syndrome MDS 72 Mg Uk 72 Phase 1b Clinical Trial 72 Naive Patients 72 kidney urologic 72 Liprotamase 72 First Patient Enrolled 72 Aeolus Pharmaceuticals Announces 72 Bosutinib 72 II Clinical Trial 72 Annamycin 72 Degarelix 72 Aliskiren 72 Present Preclinical Data 72 HCV NS5B polymerase 72 metaglidasen 72 Patient Enrollment 72 Lubiprostone 72 Phase III Pivotal 72 Ixabepilone 72 Ofatumumab 72 Safinamide 72 Achieves Primary Endpoint 72 Transdermal Patch 72 Dose Ranging Study 72 Vaccine Adjuvant 72 dasatinib Sprycel ® 72 Pulmonary Arterial Hypertension 72 Initiates Phase III 72 Pharmacokinetics PK 72 HGS ETR1 mapatumumab 72 Rigel R# 72 Angiotensin Converting Enzyme 72 sodium glucose cotransporter 72 Prolongs Survival 72 PDE4 inhibitor 72 JAK2 Inhibitor 72 TO AVOID PREGNANCY WHILE 72 multi kinase inhibitor 72 humanized therapeutic 72 Pivotal Trial 72 Trandolapril 71 Advanced Renal Cell 71 Antibody Drug Conjugate 71 Refractory Hodgkin Lymphoma 71 Denufosol 71 Immunomodulatory 71 Phase IIa Clinical Trial 71 Romiplostim 71 Antiangiogenic 71 MKC# MKC# PP 71 pan HDAC inhibitor 71 Pharmacokinetic Study 71 Epratuzumab 71 Chronic Myeloid Leukemia 71 AEG# 71 Pooled Analysis 71 2 methoxyestradiol 71 Enzyme Replacement Therapy 71 novel VDA molecule 71 blinded randomized placebo controlled 71 Systemic Delivery 71 Temsirolimus 71 Dapagliflozin 71 developing Bicifadine serotonin 71 Bevacizumab 71 Lung Cancer Drug 71 Well Tolerated 71 investigational oral inhibitor 71 recurrent metastatic ovarian cancer 71 Tyrima 71 YONDELIS 71 myelofibrosis polycythemia vera 71 Pertuzumab 71 evaluating tivozanib 71 Demonstrates Potent 71 Cethromycin 71 EOquin TM phase 71 Pazopanib 71 VEGFR2 inhibitor 71 Panzem R NCD 71 Randomized Phase II 71 Receptor Agonist 71 Pemetrexed 71 Glufosfamide 71 Phase Ib II 71 Receives Orphan Drug Designation 71 Previously Treated 71 Initiates Phase 71 SAR# [002] 71 BRIM2 71 sorafenib tablets 71 relapsed MM 71 Daclizumab 71 Prospective Randomized 71 MAGE A3 ASCI 71 GW# [003] 71 Brentuximab Vedotin SGN 71 Adjuvant Treatment 71 Immunotherapeutic 71 Tipranavir 71 Nitazoxanide 71 Antithrombin 71 HuMax EGFr 71 cetuximab Erbitux R 71 Mylan Receives Approval 71 Tumor Necrosis Factor 70 INTEGRILIN R 70 thalidomide Thalomid 70 Granted Orphan Drug 70 Teriflunomide 70 Phase III Trials 70 HCV Protease Inhibitor 70 CYC# 70 RNAi Therapeutic 70 Azacitidine 70 Mipomersen 70 JAK Inhibitor 70 Elesclomol 70 Adjunctive Therapy 70 MKC# MT 70 IAP inhibitor 70 Pegloticase 70 Decitabine 70 See CLINICAL PHARMACOLOGY 70 Cetrorelix 70 PRTX 70 OMP #R# 70 Peginterferon 70 investigational humanized monoclonal antibody 70 Monoclonal Antibody 70 LymphoStat B belimumab 70 Silodosin 70 orally bioavailable 70 Gamunex C 70 Melphalan 70 PEG SN# 70 TKB# 70 AAG geldanamycin analog 70 IMC A# 70 Preclinical Study 70 PSMA ADC 70 Files IND 70 Renal Impairment 70 fosbretabulin 70 Long Term Efficacy 70 DermaVir Patch 70 Recombinant Human 70 Bortezomib 70 Traficet EN 70 sorafenib Nexavar 70 PEGylated Fab fragment 70 Lamotrigine 70 adalimumab Humira 70 Panzem R 70 Vandetanib 70 R#/MEM # 70 Eltrombopag 70 Presents Preclinical Data 70 Aplidin R 70 AKT inhibitor 70 ZOLINZA 70 Elvitegravir 70 vapreotide acetate 70 ritonavir boosted 70 Presents Preclinical 70 Multiple Ascending Dose 70 OMP #M# 70 Benign Prostatic Hyperplasia 70 CEQ# 70 Receptor Antagonists 70 NDA Submission 70 Synta Announces 70 Tanespimycin 70 R lenalidomide 70 NS5b 70 aripiprazole Abilify 70 Valopicitabine 70 Diabetic Nephropathy 70 Phase III Trial 70 Eculizumab 70 mGluR5 NAM 70 Initiate Clinical Trial 70 NXL# 70 Fingolimod 70 Therapeutic Vaccine 70 Milestone Payment From 70 Relapsed Multiple Myeloma 70 Shows Promise Against 70 liposomal formulation 70 Cloretazine 70 Sangamo BioSciences Announces 70 Confirmatory Phase 70 brivanib 70 Oral Calcitonin 70 TNF Tumor Necrosis Factor 70 Novel Therapeutic 70 Xeloda ® 70 Therapeutic Competitors Companies 70 targeted radiotherapeutic 70 selective kinase inhibitor 70 DU #b 70 Malignant Glioma 70 Perifosine 70 mapatumumab 70 Nicotine Vaccine 70 Newly Diagnosed Multiple Myeloma 70 Advanced Melanoma 70 Boceprevir 70 IMiDs ® 70 evaluating picoplatin 70 virus HCV protease inhibitor 70 MGd 69 pan histone deacetylase 69 Double Blind Placebo 69 either acutely decompensated 69 alefacept 69 Protease Inhibitor 69 docetaxel Taxotere R 69 CYP#A# substrate 69 polymerase inhibitor 69 FDA Accepts 69 Archexin 69 Dendritic Cells 69 Protein Kinase C 69 proteasome inhibitor 69 Late Breaker 69 Apaziquone 69 alpha folate receptor 69 PNP inhibitor 69 5 HT2A inverse 69 Albuferon TM 69 albiglutide 69 Prodrug 69 Demonstrates Positive 69 accumulate preferentially 69 dependent kinase inhibitor 69 Investigational Oral 69 protein tyrosine phosphatase 1B 69 Oral Insulin 69 Transdermal Delivery 69 beta 1a 69 Disease Modifying 69 Ceflatonin R 69 Factor Receptor 69 galiximab 69 Pivotal Study 69 PRN FDA Approves 69 Oral Formulation 69 Antiviral Activity 69 potent topoisomerase II 69 Personalized Immunotherapy 69 Reports Preclinical Data 69 5 HT6 receptor 69 Glatiramer Acetate 69 sunitinib Sutent ® 69 Pirfenidone 69 Topline Results 69 Completes Enrollment 69 Improves Survival 69 Ambrisentan 69 small molecule thrombopoietin 69 PSN# [002] 69 Aptamer 69 Bayer HealthCare Onyx Pharmaceuticals 69 IND Filing 69 Investigational Drug 69 phase IIb trial 69 Resistant Hypertension 69 Talactoferrin 69 docetaxel Taxotere ® 69 midstage clinical 69 Randomized Clinical Trial 69 Antigen Specific 69 alfa 2a 69 ALN HPN 69 KRN# 69 ACE Inhibitors 69 Clinical Trial Evaluating 69 ThermoDox R 69 Orally administered 69 dasatinib Sprycel 69 Combination Treatment 69 Elagolix 69 Trial Evaluating 69 MEK inhibitor 69 IL# PE#QQR 69 Obatoclax 69 TLK# 69 Cannabinor 69 Fondaparinux 69 itraconazole Sporanox 69 aflibercept VEGF Trap 69 recurrent glioblastoma multiforme 69 unique alkylating agent 69 Exelixis XL# 69 agonistic human 69 histone deacetylase HDAC inhibitor 69 Severe Sepsis 69 refractory chronic lymphocytic 69 Vorinostat 69 Adenoviral 69 Prodarsan R 69 Peginterferon Alfa 2a 69 Ozarelix 69 Arimoclomol 69 Drug Shows Promise 69 trastuzumab Herceptin R 69 Atripla combines 69 Phase Ib clinical 69 FOLFOX6 chemotherapy regimen 69 Treatment Reduces 69 Is Well Tolerated 69 Azedra 69 Mycophenolate Mofetil 69 chimeric monoclonal antibody 69 small molecule Hedgehog 69 Granulocyte Colony Stimulating Factor 69 Darapladib 69 Small Molecule 69 SPRYCEL ® 69 Submits NDA 69 metastatic hormone refractory 69 peptidic compound 69 HQK 69 HCV SPRINT 69 familial amyloidotic polyneuropathy FAP 69 Bavituximab 69 AFREZZA TM 69 Commences Phase 69 Antifungals 69 Universal Flu Vaccine 69 Relapsed Refractory 69 Patients Treated With 69 systemic RNAi therapeutic 69 triggers apoptosis programmed 69 TMC# [002] 69 Cholesterol Lowering Drug 69 Gout Drug 69 vinca alkaloid 69 LymphoStat B TM 69 nilotinib Tasigna ® 69 gastrin analogue TT 69 Second Pivotal Phase 69 peripherally acting 69 Peginterferon alfa 2b 69 radiolabeled TM# 69 Zorbtive TM 69 Myelodysplastic Syndromes 69 Lanthanum Carbonate 69 Angiolix 69 Guanilib 69 brand ciclesonide HFA 69 ® lenalidomide 69 Perifosine KRX 69 Rheumatoid Arthritis Drug 69 Hedgehog Pathway Inhibitor 69 selective phosphodiesterase 69 Malignant Melanoma 69 cMET 69 oral dihydropyrimidine dehydrogenase DPD 69 Tarceva TM 69 Telaprevir VX 69 ARRY # 69 5 HT4 69 targeting CD# 69 Lupus Nephritis 68 CTAP# Capsules 68 Fast Track Status 68 Diabetic Neuropathy 68 CD# monoclonal antibody 68 Systemic Sclerosis 68 selective modulator 68 ATRA IV 68 Gleevec resistant 68 Gemcitabine 68 Mitoxantrone 68 mGluR5 negative 68 intranasal formulation 68 Phase #b/#a clinical 68 protein kinase inhibitor 68 Xanafide 68 Xeloda capecitabine 68 Darusentan 68 generation purine nucleoside 68 hyperphenylalaninemia HPA due 68 orally administered inhibitor 68 IAP inhibitors 68 Kinase Inhibitors 68 Bafetinib 68 Inhalation Solution 68 Hypercholesterolemia 68 plasma kallikrein inhibitor 68 Clinical Trial Data 68 acetonide FA 68 Clofarabine 68 toenail onychomycosis 68 Epilepsy Drug 68 Dose Finding 68 Chemokine Receptor 68 humanized anti 68 Signaling Pathway 68 Ocrelizumab 68 alpha antagonist 68 Dupuytren Contracture 68 Ustekinumab 68 PEGylated anti 68 Vidaza azacitidine 68 phase III isavuconazole 68 bevacizumab Avastin ® 68 investigational monoclonal antibody 68 Disease Progression 68 Imetelstat 68 pertuzumab 68 Cytarabine 68 PI3K/Akt pathway inhibitor 68 Amrubicin 68 oral Janus kinase 68 Nymox NX 68 CCR5 antagonist 68 CR# vcMMAE 68 Vimpat R 68 R roscovitine 68 Desvenlafaxine Succinate 68 AFREZZA ™ 68 Monotherapy 68 Sym# 68 Tesetaxel 68 Refractory Angina 68 RNAi Therapeutics 68 signal transduction inhibitor 68 Laquinimod 68 Vidofludimus 68 CDK inhibitor 68 HGS ETR2 68 Linaclotide 68 systemic juvenile idiopathic 68 Inhalation Aerosol 68 Rindopepimut 68 chronic eosinophilic leukemia 68 antibody MAb 68 Fluorouracil 68 Plicera 68 Trastuzumab DM1 68 Treating Chronic 68 selective antagonist 68 hypereosinophilic syndrome 68 sapacitabine CYC# 68 alvespimycin 68 Schizophrenia Drug 68 oral dual endothelin 68 Treatment Naive Patients 68 dexamethasone Decadron 68 Irinotecan 68 Xelox 68 Diabetic Foot Ulcer 68 Calcitonin 68 ATL# [001] 68 Inflammatory Markers 68 First Patient Treated 68 Piperacillin 68 FDA Approvals 68 Collaborators Present 68 metastatic malignant 68 Crofelemer budesonide foam 68 Spectrum Pharmaceuticals Announces 68 Treatment Experienced 68 bevacizumab Avastin R 68 Fulvestrant 68 Bezielle 68 Chronic HCV 68 imatinib Gleevec ® 68 riociguat 68 Asthma COPD 68 vinorelbine tartrate 68 Mimetics 68 Replacement Therapy 68 HMG CoA reductase inhibitors 68 CD4 monoclonal antibody 68 Capecitabine 68 Interferon Beta 68 Interferon Gamma 68 Oracea TM 68 ENMD # 68 generation Hsp# inhibitor 68 small molecule glucokinase 68 BMS # 68 interferon gamma 1b 68 Tocilizumab 68 Lung Cancer Trial 68 Onyx Pharmaceuticals Announces 68 Prostate Cancer Vaccine 68 Olaparib 68 Anti angiogenic 68 Fixed Dose 68 Plaque Psoriasis 68 Anticancer Activity 68 Saizen ® 68 Cardiotoxicity 68 Milestone Payment 68 Trodusquemine MSI 68 Dose Escalation Study 68 Receives Orphan Drug 68 including eniluracil ADH 68 forodesine 68 Cariprazine 68 Immunomedics Announces 68 histone deacetylase inhibitor 68 Custirsen 68 lexidronam injection 68 Begins Dosing 68 Soft Tissue Sarcoma 68 hyaluronidase enzyme 68 Polymerase Inhibitor 68 cutaneous T 68 Rilonacept 68 IgG1 monoclonal antibody 68 By JENNIFER LEARN 68 NS#/#A protease 68 CCX# 68 Sudhir Agrawal D.Phil 68 Palifosfamide 68 Interferon beta 1a 68 Nilotinib 68 Vincristine 68 Tumor Response 68 biologic DMARD 68 VIVITROL ® 68 Thiazolidinediones 68 IMiDs ® compound 68 highly selective inhibitor 68 Inflammatory Disease 68 Paraplatin ® 68 MYCAMINE 68 Diabetic Neuropathic Pain 68 Relapsing Multiple Sclerosis 68 immunotherapeutic agent 68 lenalidomide Revlimid R 68 SCH # 68 VitiGam 68 Initiates Dosing 68 Demonstrated Significant 68 Anthracycline 68 TRO# 68 HGS# 68 Initiate Phase III 68 Novel Mechanism 68 iobenguane 68 Estrogen Receptor 68 Crizotinib 68 oral nucleoside analogue 68 immunomodulating 68 Sevelamer 68 LY# [003] 68 Demonstrates Efficacy 68 Diffuse Large B 68 Entry Inhibitor 68 SAR# [004] 68 Liposomal 68 Phase Ib IIa 68 complement inhibitor eculizumab 68 ara C 68 Investigational Agent 68 Placebo Controlled 68 Roflumilast 68 mTOR inhibitor 68 Treatment Shows Promise 68 lead Aganocide compound 67 Kinesin Spindle Protein KSP 67 Previously Untreated 67 memantine HCl 67 nucleotide analog 67 Monopril 67 Renal Cell Carcinoma 67 Nucleoside 67 Sipuleucel T 67 Proc Am Soc 67 investigational protease inhibitor 67 CDK cyclin dependent 67 dose escalation clinical 67 Fluvastatin 67 R roscovitine CDK cyclin 67 Leukemias 67 Oral Spray 67 Kuvan sapropterin dihydrochloride 67 Inhaled Nitric Oxide 67 IMC #B 67 Microplasmin 67 Biomarker Study 67 Otelixizumab 67 diarrhea predominant irritable 67 Agonist MABA program 67 Paclitaxel Carboplatin 67 metastatic colorectal 67 Ribavirin causes 67 IMA# 67 oral proteasome inhibitor 67 Initiated Phase 67 chronic myeloid 67 Anti VEGF 67 Anti Inflammatory Drug 67 Medoxomil 67 Phase 1b clinical trials 67 Metastatic Prostate Cancer 67 topical gel formulation 67 Solid Tumors 67 FOLFOX6 67 reslizumab 67 Nuvelo Announces 67 IMiDs 67 Alinia 67 Receives Fast Track 67 oral renin inhibitor 67 receptor modulators 67 vascular disrupting agent 67 Pegylated Interferon 67 PrevOnco 67 HCV protease 67 Treat Heart Failure 67 Heart Transplant Recipients 67 Randomized Double Blind 67 Chemotherapeutic 67 CYP#A# isoenzyme 67 demonstrated antitumor activity 67 IMiDs R 67 Study Showed 67 Darinaparsin 67 RhuDex R 67 Angiotensin 67 Shows Promising 67 Multicenter Randomized 67 JAK1 67 Presents Positive Preclinical 67 Novel Inhibitor 67 Adalimumab 67 Allergic Rhinitis 67 Patients Receiving 67 novel emulsion formulation 67 Oritavancin 67 Pegylated 67 Eniluracil 67 TNF Blockers 67 Bicalutamide 67 Namenda ® 67 Aplidin 67 5 Fluorouracil 67 treatment naive genotype 67 Simulect 67 TRANSDUR ® 67 benign prostatic hypertrophy BPH 67 INCB# [001] 67 Nanoemulsion 67 Febuxostat 67 Drug Combo 67 TRACON Pharmaceuticals 67 Deferiprone 67 Myeloma Patients 67 Squalamine 67 CCX# B 67 5 fluorouracil leucovorin 67 NS5B polymerase 67 Newly Diagnosed 67 essential thrombocythemia ET 67 Apixaban 67 ixabepilone 67 huN# DM1 67 Moxifloxacin 67 Demonstrate Significant 67 Vaccine Candidate 67 SUTENT ® 67 Cyclooxygenase 2 67 Orally Active 67 tigecycline 67 Arranon 67 TRAIL R1 67 Alogliptin 67 Aviptadil 67 Diabetic Macular Edema 67 MKC# 67 FDA Okays 67 Fluticasone 67 oral picoplatin 67 Brain Metastases 67 bortezomib Velcade R 67 FDA APPROVES 67 GRN# 67 novel tubulin binding 67 Telik Announces 67 RAS MAPK pathway 67 Potent Inhibitor 67 JVRS 67 phase IIb clinical 67 Cetrorelix pamoate 67 miconazole Lauriad ® 67 Sustained Release 67 Treatment Regimen 67 Patient Enrolment 67 Tesamorelin 67 Philadelphia Chromosome Positive 67 Mouse Model 67 EOquin TM 67 Zolinza 67 octreotide acetate 67 5 HT3 antagonist 67 MTP inhibitor 67 Therapeutic Efficacy 67 DOXIL 67 RELOVAIR ™ 67 Medullary Thyroid Cancer 67 cromolyn sodium 67 Symadex 67 inflammatory PDE 67 Bare Metal Stent 67 Vidaza ® 67 Receptor Antagonist 67 Alocrest 67 E1 INT TM 67 RhuDex ® 67 Miconazole 67 Randomized Double Blind Placebo 67 Hepatitis C Infection 67 ergot derivatives 67 pharmacogenomic translational research 67 Pathway Inhibitor 67 Intervention Effectiveness 67 label Lipofen R 67 Mouse Models 67 hormone LHRH antagonist 67 Quinamed 67 Pivotal Clinical Trial 67 Abstract Accepted 67 Preclinical Efficacy 67 TRANSDUR ™ 67 Dementia Related Psychosis 67 myelodysplastic myeloproliferative diseases 67 TYGACIL 67 Angiocept 67 Acute Exacerbations 67 Shows Efficacy 67 R Saizen R 67 Levetiracetam 67 Aurora kinase 67 Pivotal Trials 67 Phase 2a Study 67 Tiotropium 67 induced macular edema 67 pharmacologically active isomer 67 PDE# 67 Earns Milestone Payment 67 rivastigmine Exelon 67 Clot Busting 67 echinocandin 67 candidates Azedra TM 67 targeted antifolate 67 Acute Decompensated Heart Failure 67 Lymphocytic 67 Pimavanserin 67 selective A2A adenosine receptor 67 Myelofibrosis 67 Janus Kinase 67 Arno Therapeutics 67 Investigational eFlow Nebulizer System 67 Curaxin CBLC# 67 Alemtuzumab 67 Ganciclovir 67 Imprime PGG 67 seliciclib CYC# 67 delivers fluocinolone acetonide FA 67 Phase Ib Clinical Trial 67 Anticancer Agent 67 ZD# [001] 67 multicenter Phase II 67 Initiates Phase 2b 67 Controlled Study 67 tenofovir Viread 67 teriflunomide 67 Anidulafungin 67 Remission Maintenance 67 Pyridorin 67 HGS ETR1 67 Randomized Study 67 PRT# 67 peptibody 67 potent suppressor 67 Telbivudine 67 nilotinib Tasigna 67 EnteroMedics proprietary neuroblocking technology 67 Topotecan 67 phase Ib 67 human IgG1 monoclonal 67 Tofacitinib 67 JAK2 inhibitor 67 D aspartate NMDA receptor 67 Eraxis 67 receptor partial agonist 67 Antitumor 67 Pruvel TM 67 Paliperidone Palmitate 67 BRAF inhibitor 67 Clolar ® 67 Prostate AdenoCarcinoma Treatment 67 Vascular Disrupting Agent 67 K ras mutations 67 Trastuzumab 67 Dacogen decitabine 67 GSK# [001] 67 Aztreonam Lysine 67 Vaccine Adjuvants 67 Generic Version 67 Velcade bortezomib 67 ACTEMRA TM 67 Vitrasert R 67 pathophysiological effects 67 immunomodulator 67 angiogenesis inhibitor 67 PEGINTRON TM 67 Completes Dosing 67 cilengitide 67 Ecallantide 67 Pyridorin TM 67 ganetespib 67 Vildagliptin 67 Carbidopa Levodopa 67 Subgroup Analysis 67 TELINTRA 67 Zileuton 67 Systemic lupus erythematosus SLE 67 Clinical Study Shows 67 ST Elevation Myocardial 67 BENICAR HCT 67 Therapeutic Antibody 67 SNT MC# 67 BENLYSTA TM 67 Capsules CII 67 Treatment Resistant 67 HCl Injection 67 Commence Phase 67 Unfractionated Heparin 67 DOXIL R 67 HER2 Positive Breast Cancer 67 Blood Pressure Drug 67 Tolvaptan 67 glatiramer acetate 67 HCV polymerase 67 humanized monoclonal 67 SPC# [001] 67 VAPRISOL 67 Anticoagulant 67 Nanobody 67 Exemestane 67 Peptide YY 67 prescribed proton pump 67 estrogen receptor antagonist 67 Recurrent Breast Cancer 67 LAB CGRP 67 talabostat 67 Anticancer Drugs 67 XYOTAX TM 67 de novo kidney transplant 67 DNA intercalator 67 Forodesine 67 busulfan 67 Adjunctive 67 gefitinib Iressa 67 Tegretol carbamazepine 67 Low Dose 67 indinavir Crixivan 67 candesartan cilexetil 66 sodium thiosulfate STS 66 DNA methyltransferase inhibitors 66 tyrosine kinase inhibitor TKI 66 denileukin diftitox 66 GRNOPC1 contains 66 Valsartan 66 Janus kinase 66 Tumor Targeting 66 Tasimelteon 66 AEGR 66 Respiratory Virus 66 Panzem 66 treat benign prostatic 66 Novel Small Molecule 66 Parathyroid Hormone 66 Triapine 66 visilizumab 66 methylnaltrexone bromide 66 Analogs 66 Recurrent Glioblastoma 66 Camptosar ® 66 Myocet 66 OXi# 66 Schizophrenia Treatment 66 Kahalalide F 66 Lixisenatide 66 Endothelial Cells 66 Gastrointestinal Stromal Tumors 66 eosinophilic asthma 66 OMNARIS HFA 66 bexarotene 66 Azathioprine 66 tetracycline antibiotic 66 novel topoisomerase 66 long acting muscarinic 66 reduce serum phosphate 66 huC# DM4 66 Formoterol 66 Celebrex celecoxib